04-02-2016 дата публикации
Номер: US20160030373A1
Принадлежит:
Methods for treating a glucose-related metabolic disorder (e.g., diabetes) comprising administration of 2-aminoadipic acid (2-AAA) to subjects in need thereof. Also described are methods for predicting a subject's risk of developing a glucose-related metabolic disorder, and to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder (e.g., diabetes). 19.-. (canceled)10. A method for determining risk of developing diabetes in a subject , the method comprising:determining a level of 2-aminoadipic acid (2-AAA) in a test sample from the subject;comparing the level of 2-AAA in the test sample to a reference level; anddetermining the subject has an increased risk of developing diabetes when the test sample has an increased level of 2-AAA as compared to the reference level.11. The method of claim 10 , wherein the test sample comprises serum or plasma from the subject.12. The method of claim 10 , wherein the subject has normal glucose tolerance.13. The method of claim 10 , further comprising selecting a treatment based on the level of 2-aminoadipic acid in the test sample.14. The method of claim 13 , further comprising administering the selected treatment to the subject.15. The method of claim 13 , wherein the treatment comprises administering to the subject an effective amount of at one or more additional anti-diabetes compound selected from the group consisting of acarbose claim 13 , miglitol claim 13 , metformin claim 13 , phenformin claim 13 , buformin claim 13 , repaglinide claim 13 , nateglinide claim 13 , tolbutamide claim 13 , chlorpropamide claim 13 , tolazamide claim 13 , acetohexamide claim 13 , glyburide claim 13 , glipizide claim 13 , glimepiride claim 13 , gliclazide claim 13 , troglitazone claim 13 , rosiglitazone claim 13 , pioglitazone claim 13 , peptide analogs claim 13 , glucagon-like peptide I (GLP1) and analogs thereof claim 13 , GLP agonists claim 13 , vildagliptin sitagliptin; dichloroacetic acid; amylin claim 13 , ...
Подробнее